MacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic Priorities Newly-appointed President and CEO, Eric Risser, outlines strategic priorities for 2025 and 2026 Received $70 million upfront cash payment from Sagard Healthcare Partners under a royalty purchase agreement for ZYNYZ® Cash, cash equivalents and marketable securities of $176.5 million as of June 30, 2025; cash runway through first half of 2027 ROCKVILLE, Md., Aug. 14, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing inn...
MacroGenics Appoints Eric Risser as President and Chief Executive Officer ROCKVILLE, MD, Aug. 13, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company developing innovative antibody-based therapeutics for the treatment of cancer, today announced that effective as of August 13, 2025, Eric Risser has been appointed President, Chief Executive Officer and to the Board of Directors. Mr. Risser has served as Chief Operating Officer at MacroGenics since 2022, overseeing several key company functions and has led the Company’s corporate development...
PDS Biotech Reports Second Quarter 2025 Financial Results and Provides Clinical Programs Update Multiple Abstracts Presented at the 2025 American Society of Clinical Oncology Annual Meeting Conference call and webcast today at 8:00 a.m. Eastern Time PRINCETON, N.J., Aug. 13, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today provided a business update and reported financial results for the second quarter ended ...
PDS Biotech Announces Conference Call and Webcast for Second Quarter 2025 Financial Results PRINCETON, N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company will host a conference call to report financial results for the quarter ended June 30, 2025 and provide a clinical programs update on Wednesday, August 13, 2025 at 8:00 am Eastern Time. Conference Call Details Date: August 13, 202...
Transocean Ltd. Reports Second Quarter 2025 Results Three months ended Three months ended June 30,2025 March 31,2025 sequentialchange June 30,2024 year-over-yearchange(In millions, except per share amounts, percentages and backlog) Contract drilling revenues$988 $906 $82 $861 $127 Revenue efficiency (1) 96.6 % 95.5 % 96.9 % Operating and maintenance expense$599 $618 $19 $534 $(65)Net loss attributable to controlling interest$(938) $(79) $(859) $(123) $(815)Basic loss per share$(1.06) $(0.09) $(0.97) $(0.15) $(0.91)...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.